XML 44 R34.htm IDEA: XBRL DOCUMENT
v3.22.2

Commitments and Contingencies (Details Narrative) - USD ($) |  |  |  |  |  |  |  |  |  | 2 Months Ended | 3 Months Ended | 6 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 10, 2022 | Apr. 09, 2021 | Feb. 05, 2021 | Aug. 12, 2020 | Sep. 12, 2018 | Aug. 20, 2018 | Mar. 22, 2018 | Sep. 14, 2015 | Dec. 24, 2013 | Aug. 31, 2020 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contractual commitment |  |  |  |  |  |  |  |  |  |  | $ 8,147,000 |  | $ 8,147,000 |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  | 164,810 | $ 262,415 | 623,261 | $ 705,941 |
City of Hope [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 296,000 |  | 296,000 |  |
GEIS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount related to milestone payment |  |  |  |  |  |  |  |  |  |  |  |  | 67,582 |  |
NDA Consulting Corp [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consulting and advisory fee |  |  |  |  |  |  |  |  | $ 4,000 |  | 4,000 | 4,000 | 8,000 | 8,000 |
Clinical Trial Research Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advance amount related to milestone payment |  |  |  |  |  |  |  |  |  |  |  |  | 6,073 | 10,309 |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  | 9,405 | 17,693 |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  | $ 114,082 |  |
Aggregate commitments expected, description |  |  |  |  |  |  |  |  |  |  |  |  | The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $594,000 as of June 30, 2022, which is expected to be incurred through December 31, 2025 |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 594,000 |  | $ 594,000 |  |
Collaboration Agreement [Member] | GEIS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advance amount related to milestone payment |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 24,171 |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  | $ 155,053 |  |
Aggregate commitments expected, description |  |  |  |  |  |  |  |  |  |  |  |  | The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $4,166,000 as of June 30, 2022, which is expected to be incurred through December 31, 2025 |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 4,166,000 |  | $ 4,166,000 |  |
Collaboration Agreement [Member] | BioPharmaWorks LLC [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consulting and advisory fee |  |  |  |  |  |  |  | $ 10,000 |  |  |  |  |  |  |
Reimbursed expense |  |  |  |  |  |  |  |  |  |  | 30,000 | 30,000 | 60,000 | 60,000 |
Development Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  | 0 |  | 292,293 |  |
Other Clinical Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  | 1,138,000 |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 20,000 |  | 20,000 |  |
Clinical Research Support Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 800,000 |  | 800,000 |  |
Clinical Research Support Agreement [Member] | City of Hope [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  | 0 | 285,020 | 0 | 525,528 |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 2,433,000 |  | 2,433,000 |  |
Work Order Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  | 99,723 |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 862,000 |  | 862,000 |  |
Work Order Agreement [Member] | City of Hope [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advance amount related to milestone payment |  |  |  |  |  |  |  |  |  |  | 11,235 | 10,773 | 15,735 | 14,313 |
Research and development costs |  |  | $ 335,000 |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 40,361 |  | 40,361 |  |
Work Order Agreement [Member] | Theradex Systems, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  | $ 954,000 |  |  |  |  |  | 4,558 | 7,540 | 7,839 | 8,481 |
Material Transfer Agreement [Member] | INSERM [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  | $ 0
Material Transfer Agreement [Member] | INSERM [Member] | Development Milestones [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  | $ 1,750,000 |  |  |  |  |  |  |  |
Material Transfer Agreement [Member] | INSERM [Member] | Commercial Milestones [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  | $ 6,500,000 |  |  |  |  |  |  |  |
Exclusive License Agreement [Member] | First Four Years [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum payments for royalties |  |  |  |  |  |  |  |  |  |  |  |  | 50,000 |  |
Exclusive License Agreement [Member] | Five Years And Thereafter [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum payments for royalties |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 |  |
Exclusive License Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable license issue fee |  |  |  |  |  | $ 25,000 |  |  |  |  |  |  |  |  |
Annual license maintenance fee |  |  |  |  |  | 25,000 |  |  |  |  |  |  |  |  |
Payments on non-refundable milestone |  |  |  |  |  | $ 1,897,000 |  |  |  |  |  |  |  |  |
Amount charges to operations |  |  |  |  |  |  |  |  |  |  | 6,233 | 6,233 | 12,398 | 12,397 |
Employment Agreement [Member] | Executive Officers [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Salary and Wage, Excluding Cost of Good and Service Sold |  |  |  |  |  |  |  |  |  | $ 640,000 |  |  |  |  |
Agreement term description |  |  |  |  |  |  |  |  |  | one-year period |  |  |  |  |
Employment Agreement [Member] | Dr.James [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual compensation |  | $ 775,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Master Service Agreement [Member] | Foundation for Angelman Syndrome Therapy [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of proceeds agree to pay under agreement |  |  |  | 5.00% |  |  |  |  |  |  |  |  |  |  |
Maximum amount received under agreement |  |  |  | $ 250,000 |  |  |  |  |  |  |  |  |  |  |
Development Collaboration Agreement [Member] | Netherlands Cancer Institute [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advance amount related to milestone payment |  |  |  |  |  |  |  |  |  |  | 48,886 |  | 103,116 |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  | $ 158,364 |  |
Aggregate commitments expected, description |  |  |  |  |  |  |  |  |  |  |  |  | The Company’s aggregate commitment pursuant to this collaboration agreement, less amounts previously paid to date, totaled approximately $361,000 as of June 30, 2022, which is expected to be incurred through June 30, 2025. |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 361,000 |  | $ 361,000 |  |
MRI Global [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advance amount related to milestone payment |  |  |  |  |  |  |  |  |  |  | 19,597 | $ 15,423 | 20,353 | $ 17,432 |
Contract price | $ 273,980 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Trial Monitoring Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | $ 64,000 |  | $ 64,000 |  |

X
- Definition Advance amount related to milestone payment. + References No definition available. + Details
Name: | LIXT_AdvanceAmountRelatedToMilestonePayment
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Agreement term description. + References No definition available. + Details
Name: | LIXT_AgreementTermDescription
Namespace Prefix: | LIXT_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount related to milestone payment. + References No definition available. + Details
Name: | LIXT_AmountRelatedToMilestonePayment
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Company is obligated to pay annual license maintenance fee.. + References No definition available. + Details
Name: | LIXT_AnnualLicenseMaintenanceFee
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Consulting and advisory quarterly cash fee. + References No definition available. + Details
Name: | LIXT_ConsultingAndAdvisoryCashFee
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contract price + References No definition available. + Details
Name: | LIXT_ContractPrice
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum amount received under agreement. + References No definition available. + Details
Name: | LIXT_MaximumAmountReceivedUnderAgreement
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payments. + References No definition available. + Details
Name: | LIXT_MilestonePayments
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Company is obligated to pay non refundable license issue fee.. + References No definition available. + Details
Name: | LIXT_NonRefundableLicenseIssueFee
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Company agreed to pay non-refundable milestone payments which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones. + References No definition available. + Details
Name: | LIXT_PaymentsOnNonrefundableMilestone
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of proceeds agree to pay under agreement + References No definition available. + Details
Name: | LIXT_PercentageOfProceedsAgreeToPayUnderAgreements
Namespace Prefix: | LIXT_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reimbursement expense. + References No definition available. + Details
Name: | LIXT_ReimbursementExpense
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments. + References No definition available. + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of expense for employee benefit and equity-based compensation. + References No definition available. + Details
Name: | us-gaap_EmployeeBenefitsAndShareBasedCompensation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense. + References No definition available. + Details
Name: | us-gaap_OperatingCostsAndExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details
Name: | us-gaap_OtherCommitment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Description of the nature and terms of commitment. + References No definition available. + Details
Name: | us-gaap_OtherCommitmentsDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash paid for royalties during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_PaymentsForRoyalties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold. + References No definition available. + Details
Name: | us-gaap_SalariesWagesAndOfficersCompensation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_OtherClinicalAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_MaterialTransferAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_INSERMMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=LIXT_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=LIXT_CommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VestingAxis=LIXT_FirstFourYearsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VestingAxis=LIXT_FiveYearsAndThereafterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=LIXT_ExecutiveOfficersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=LIXT_Dr.JamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_MasterServiceAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_FoundationForAngelmanSyndromeTherapyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialMonitoringAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |